title: [Cytostatic therapy of tumors under conditions of partial synchronisation with particular reference to malignant tumors of the testicle (author's transl)].
abstract: Cytostatic therapy under conditions of "partial synchronisation" is reported. 12 patients with extensive metastases of malignant testicular tumors and 5 other patients with other rapidly growing metastasizing tumors were treated. They had all previously undergone extensive operation, irradiation and some also treatment with cytostatics. Vincristine/ifosfamide and bleomycin/ifosfamide were given as stosstherapy and trofosfamid (Ixoten) as maintenance therapy. There was complete remission of the lung metastases in 8 of the metastasizing testicular tumors. Retroperitoneal and supraclavicular metastases became operable. In 2 patients there was a partial remission lasting 4-6 months. Complete remission could be obtained in the other patients.
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005134:Eye Neoplasms / Q000188:drug therapy; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012175:Retinoblastoma / Q000188:drug therapy; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D013724:Teratoma / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001761:Bleomycin; D014750:Vincristine; D007069:Ifosfamide
vernacular_title: Zytostatische Tumortherapie unter Teilsynchronisationsbedingungen mit besonderer Berücksichtigung der malignen Hodentumoren